Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Net Cash Flow: 2019-2025

Historic Net Cash Flow for Eton Pharmaceuticals (ETON) over the last 7 years, with Sep 2025 value amounting to $11.7 million.

  • Eton Pharmaceuticals' Net Cash Flow rose 357.42% to $11.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.9 million, marking a year-over-year increase of 1032.01%. This contributed to the annual value of -$6.5 million for FY2024, which is 226.93% down from last year.
  • Latest data reveals that Eton Pharmaceuticals reported Net Cash Flow of $11.7 million as of Q3 2025, which was up 47.53% from $8.0 million recorded in Q2 2025.
  • In the past 5 years, Eton Pharmaceuticals' Net Cash Flow ranged from a high of $11.7 million in Q3 2025 and a low of -$8.3 million during Q4 2021.
  • Over the past 3 years, Eton Pharmaceuticals' median Net Cash Flow value was $1.0 million (recorded in 2024), while the average stood at $1.9 million.
  • As far as peak fluctuations go, Eton Pharmaceuticals' Net Cash Flow skyrocketed by 22,812.50% in 2022, and later crashed by 680.79% in 2024.
  • Eton Pharmaceuticals' Net Cash Flow (Quarterly) stood at -$8.3 million in 2021, then spiked by 135.25% to $2.9 million in 2022, then slumped by 123.30% to -$682,000 in 2023, then plummeted by 680.79% to -$5.3 million in 2024, then spiked by 357.42% to $11.7 million in 2025.
  • Its Net Cash Flow stands at $11.7 million for Q3 2025, versus $8.0 million for Q2 2025 and $2.5 million for Q1 2025.